Ocrevus is the 15th disease-modifying therapy (DMT) to launch for the treatment of relapsing forms of multiple sclerosis (MS) in the United States. Its novel B-cell-depleting mechanism offers potent efficacy, while its selectivity provides a safety profile that may set it apart from other highly efficacious—but risk-prone—DMTs. A competitive price offering from Genentech/Roche coupled with a clean, unrestrictive label will ease neurologists’ incorporation of Ocrevus into practice. DRG’s launch-tracking series will examines how the perception and performance of Ocrevus evolves through year 1 one in an MS market still waiting for a the DMT that balances efficacy and risk better than Tysabri or Tecfidera and in a field that perennially debates the merits of early, aggressive intervention.

What you will learn in this content:

  • What are is U.S. neurologists’ awareness of and familiarity with Ocrevus, and what are their perceptions of this product?
  • For which patients are neurologists prescribing Ocrevus, what are their reasons for prescribing in relapsing MS, and how satisfied are they with Ocrevus?
  • What are the promotional messages and activities that Genentech and Roche are employing in support of the Ocrevus launch in relapsing MS?
  • How does the trial and adoption of Ocrevus compare with other recent product launches in the relapsing MS market? How do adopters and nonadopters of Ocrevus in the largest MS subpopulation compare across key metrics?

Product description:

Launch Tracking: Ocrevus Wave 1 (US) Relapsing Forms of Multiple Sclerosisis a three-wave series based on primary research data collected at 1, 6, and 12 months post-commercial launch with U.S. physicians. The research captures physicians’ awareness, perceptions, and usage of the launched product, as well as anticipated future trends. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other launched agents.

Table of contents

  • Multiple Sclerosis - Emerging Therapies - Ocrevus Relapsing Forms Of Multiple Sclerosis - Wave 2 (US)
    • Key Findings
      • Benchmarking Ocrevus Launch Success vs. the Competition
        • Six Months Postlaunch, Ocrevus Outperforms Most Benchmark DMTs on Measures of Physician Receptivity and Uptake
        • Benchmarking Ocrevus Launch Success vs. Other Launched Drugs
      • Prescriber and Nonprescriber Profiles
        • Differences Between Ocrevus Prescribers and Nonprescribers for Relapsing Forms of MS
        • Differences Between Ocrevus Prescriber and Nonprescriber Profiles
      • Ocrevus Awareness and Perceptions
        • Unaided and Aided Awareness of Ocrevus
          • Unaided Awareness of Drugs Approved or Launched for the Treatment of MS
          • Aided Awareness of Ocrevus
          • Aided Awareness of the Comparator Used in Ocrevus's Pivotal Clinical Trials in Relapsing Forms of MS
          • Aided Awareness of Ocrevus's Indication
          • Aided Awareness of Ocrevus's Mechanism of Action and Route of Administration
          • Aided Awareness of Ocrevus's Dosing Interval
          • Aided Awareness of Ocrevus's Clinical Profile
        • Familiarity with Ocrevus
          • Neurologists' Familiarity with Ocrevus Remains High at Six Months Postlaunch
          • Level of Familiarity with Ocrevus
        • Sources of Familiarity with Ocrevus
          • Sources of Familiarity for Ocrevus Are More Marketing-Based at Six Months Postlaunch
        • Initial Reaction to and Interest in Ocrevus
          • Reaction to and Interest in Ocrevus Remains High at Six Months Postlaunch
          • Ocrevus's Product Profile in Relapsing Forms of MS
          • Ocrevus Information Requiring Additional Information
          • Initial Reaction to Ocrevus
          • Level of Interest in Learning More About Ocrevus
        • Impressions of Ocrevus
          • Unaided Advantages of Ocrevus
          • Unaided Disadvantages of Ocrevus
          • Statement Agreements About Ocrevus for Relapsing Forms of MS
          • Statement Agreements About Ocrevus for Relapsing Forms of MS (Mean)
          • Rating of Ocrevus's Risk-Benefit Balance for Relapsing Forms of MS
        • Prescriber and Nonprescriber Profiles
          • Wave 2 Ocrevus Prescribers Continue to Show a Tendency Toward More-Aggressive Treatment of MS than Nonprescribers
          • Differences Between Ocrevus Prescriber and Nonprescriber Profiles
      • Ocrevus Trial and Use
        • Willingness to Prescribe Ocrevus
          • Surveyed Neurologists' Willingness to Prescribe Ocrevus Remains High at Six Months Postlaunch
          • Impact of Clinical and Nonclinical Attributes on Willingness to Prescribe Ocrevus in Relapsing Forms of MS
          • Mean Impact of Clinical and Nonclinical Attributes on Willingness to Prescribe Ocrevus in Relapsing Forms of MS
        • Number of Patients Currently Receiving Ocrevus
          • Six Months Postlaunch, Robust Uptake of Ocrevus for Relapsing Forms of MS Continues, Mostly in Switch Situations
          • Number of Relapsing MS Patients Prescribed Ocrevus
          • Ocrevus Discontinuation Rate in Relapsing Forms of MS
          • Mean Ocrevus Discontinuation Rate in Relapsing Forms of MS
          • Reasons for Discontinuing Ocrevus
          • Current Use of DMTs in RR-MS and Relapsing SP-MS Patients
          • Source of Business for Current Ocrevus-Treated Relapsing MS Patients
          • Source Therapy for Current Relapsing MS Patients Switched to Ocrevus
          • Number of Prior Therapies for Relapsing MS Patients Switched to Ocrevus
          • Reasons for Starting/Switching to Ocrevus in Relapsing Forms of MS
          • Relapsing Forms of MS Patient Inquiries About Ocrevus
          • Mean Number of Relapsing MS Patients Inquiring About Ocrevus
          • Percentage of Relapsing MS Patients Starting Ocrevus Following a Request
          • Ocrevus Follow-Up Visits in Relapsing MS
          • Ocrevus Treatment Response in Relapsing MS
          • Percentage of Relapsing MS Patients Ever Treated with Ocrevus Experiencing Select Adverse Events
        • Reasons for Not Yet Prescribing Ocrevus
          • Ocrevus Nonprescribers at Six Months Postlaunch Cite Safety, High Patient Copays, and Familiarity as Barriers to Use
          • Reasons for Not Prescribing Ocrevus for Relapsing Forms of MS
          • Obstacles to Prescribing Ocrevus in Relapsing Forms of MS
        • Anticipated Ocrevus Use
          • At Six Months Postlaunch, Neurologists Continue to Expect Strong Uptake of Ocrevus in Relapsing Forms of MS
          • Anticipated Timing for Ocrevus Prescribing for Relapsing Forms of MS Among Current Nonprescribers
          • Percentage of Relapsing MS Patients Who Are Ocrevus Candidates, by Disease Classification
          • Percentage of Relapsing MS Patients Who Are Ocrevus Candidates, by Treatment Situation
          • Current and Anticipated DMT Treatment Rate in Relapsing Forms of MS
          • Mean Current and Anticipated DMT Treatment Rate in Relapsing Forms of MS
          • Current and Anticipated Brand Allocation Among DMT-Treated RR-MS Patients
          • Current and Anticipated Brand Allocation Among DMT-Treated SP-MS Patients
        • Ocrevus Performance on Key Attributes
          • Surveyed Neurologists Continue to Voice High Satisfaction with Ocrevus and Perceive a Safety Advantage over Zinbryta and Lemtrada
          • Prescribers' Overall Satisfaction with Ocrevus in Relapsing Forms of MS
          • Statement Agreements Comparing Ocrevus with Other DMTs in the Context of Relapsing Forms of MS
          • Mean Ratings on Statement Agreements Comparing Ocrevus with Other DMTs in the Context of Relapsing Forms of MS
          • Current Reimbursement Limitations on Ocrevus in the Context of Treating Relapsing Forms of MS
          • Rating of Ocrevus's Performance on Clinical and Nonclinical Attributes in the Context of Treating Relapsing Forms of MS
          • Mean Ratings of Ocrevus's Performance on Clinical and Nonclinical Attributes in the Context of Treating Relapsing Forms of MS
      • Effectiveness of Face-to-Face Detailing for Ocrevus
        • Ocrevus Sales Representative Frequency and Reach
          • More Physicians Report Ocrevus Sales Representative Contact at Six Months Postlaunch
          • Sales Representative Detailing Reach
        • Satisfaction with Ocrevus Sales Representative
          • Surveyed Neurologists Report High Satisfaction with Ocrevus Sales Representatives at Six Months Postlaunch
          • Mean Satisfaction with Ocrevus Sales Representative
        • Ocrevus Message Recall
          • Ocrevus Message Recall at Six Months Postlaunch Centered on Approval for Relapsing Forms of MS and PP-MS
          • Unaided Ocrevus Message Recall During Recent Detail
          • Aided Ocrevus Message Recall During Recent Detail
      • Methodology
        • Primary Market Research Methodology
        • U.S. Region of Practice
        • State Location of Practice
        • Patient Allocation by Disease Classification
        • Mean Patient Allocation by Disease Classification
        • Recentage of SP-MS Patients Who Suffer Superimposed Relapses
        • Current DMT Treatment Rate by Disease Classification
        • Years in Practice Post-Residency
        • Practice Setting
        • Practice Location
      • Appendix
        • Reasons for Never Prescribing Ocrevus
        • Abbreviations

    Author(s): Natalie Taylor, PhD; Jonathan Searles; Sarah Soucy

    Natalie Taylor, Ph.D. is a Principal Business Insights Analyst with the central nervous system/ophthalmology disorders team at Decision Resources Group. She has over ten years of experience authoring primary and market research reports for pharmaceutical industry clients across multiple psychiatry, pain, neurology, and ophthalmology therapy areas.

    Prior to joining DRG, Dr. Taylor worked at QuintilesIMS as manager of the central nervous system portfolio of Disease Insights market forecasting offerings. She completed her Ph.D. in Physiology at Dartmouth College in Hanover, New Hampshire, where she studied the role of serotonergic neurons in the medullary raphe on modulating respiratory responses in mammals. She holds a B.S. in Biology from Dickinson College in Carlisle, Pennsylvania.

    Jonathan W. Searles is a Senior Director in the CNS/Ophthalmology unit at DRG, overseeing the neurology research stream. Prior to joining DRG, Mr. Searles received a B.A. degree, summa cum laude, from Brandeis University; during this time, Mr. Searles conducted research projects at the Harvard University Peabody Museum and at Brandeis.

    Sarah Soucy, M.S., is a Business Insights Analyst with the central nervous system/ophthalmology disorders group at Decision Resources Group. She has authored primary research and insights for dry and wet age-related macular degeneration and multiple sclerosis.

    Prior to joining DRG, Ms. Soucy spent six years on the client side as a scientist at Pfizer in the inflammation and immunology research group with both in vitro and in vivo experience. She earned her B.S. in Animal Science with a Bioscience and Technology option and her M.S. in Nutritional Sciences from the University of New Hampshire, Durham, where she studied disordered metabolism


    Related Reports

    Multiple Sclerosis - Landscape & Forecast - Disease Landscape & Forecast

    The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will c...

    View Details

    Multiple Sclerosis | Disease Landscape and Forecast | G7 | 2020

    The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will continue to fragment as new entrants drive further shifts in a complicated treatment alg...

    View Details

    Multiple Sclerosis - Current Treatment - Detailed, Expanded Analysis (US)

    Three disease-modifying therapies (DMTs)—EMD Serono’s Mavenclad, Novartis’s Mayzent, and Biogen’s Vumerity—joined the crowded U.S. multiple sclerosis (MS) market just...

    View Details

    Multiple Sclerosis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis Multiple Sclerosis 2020 – Main Report Dashboard (US)

    With more than a dozen immunomodulatory disease-modifying therapies (DMTs) available to treat multiple sclerosis (MS) and more in the pipeline, the treatment journey for U.S. MS patients continues...

    View Details